ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer

Jordan M. Reese, Elizabeth S. Bruinsma, David G Monroe, Vivian Negron, Vera Jean Suman, James N. Ingle, Matthew Philip Goetz, John R Hawse

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Triple negative breast cancer (TNBC), which comprises approximately 15% of all primary breast cancer diagnoses, lacks estrogen receptor alpha, progesterone receptor and human epidermal growth factor receptor 2 expression. However, we, and others, have demonstrated that approximately 30% of TNBCs express estrogen receptor beta (ERβ), a nuclear hormone receptor and potential drug target. Treatment of ERβ expressing MDA-MB-231 cells with estrogen or the ERβ selective agonist, LY500307, was shown to result in suppression of cell proliferation. This inhibitory effect was due to blockade of cell cycle progression. In vivo, estrogen treatment significantly repressed the growth of ERβ expressing MDA-MB-231 cell line xenografts. Gene expression studies and ingenuity pathway analysis identified a network of ERβ down-regulated genes involved in cell cycle progression including CDK1, cyclin B and cyclin H. siRNA mediated knockdown or drug inhibition of CDK1 and CDK7 in TNBC cells resulted in substantial decreases in proliferation regardless of ERβ expression. These data suggest that the tumor suppressive effects of ERβ in TNBC result from inhibition of cell cycle progression, effects that are in part mediated by suppression of CDK1/7. Furthermore, these data indicate that blockade of CDK1/7 activity in TNBC may be of therapeutic benefit, an area of study that has yet to be explored.

Original languageEnglish (US)
Pages (from-to)96506-96521
Number of pages16
JournalOncotarget
Volume8
Issue number57
DOIs
StatePublished - Jan 1 2017

Fingerprint

CDC2 Protein Kinase
Triple Negative Breast Neoplasms
Estrogen Receptor beta
Cell Cycle
Cyclin H
Estrogens
Cyclin B
Estrogen Receptor alpha
Progesterone Receptors
Cytoplasmic and Nuclear Receptors
Heterografts
Pharmaceutical Preparations
Small Interfering RNA
Cell Proliferation
Breast Neoplasms
Gene Expression
Cell Line
Growth

Keywords

  • CDK
  • Cell cycle
  • ERβ
  • Estrogen
  • TNBC

ASJC Scopus subject areas

  • Oncology

Cite this

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. / Reese, Jordan M.; Bruinsma, Elizabeth S.; Monroe, David G; Negron, Vivian; Suman, Vera Jean; Ingle, James N.; Goetz, Matthew Philip; Hawse, John R.

In: Oncotarget, Vol. 8, No. 57, 01.01.2017, p. 96506-96521.

Research output: Contribution to journalArticle

Reese, Jordan M. ; Bruinsma, Elizabeth S. ; Monroe, David G ; Negron, Vivian ; Suman, Vera Jean ; Ingle, James N. ; Goetz, Matthew Philip ; Hawse, John R. / ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. In: Oncotarget. 2017 ; Vol. 8, No. 57. pp. 96506-96521.
@article{197d27511c0344918d20f6f3af2becf5,
title = "ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer",
abstract = "Triple negative breast cancer (TNBC), which comprises approximately 15{\%} of all primary breast cancer diagnoses, lacks estrogen receptor alpha, progesterone receptor and human epidermal growth factor receptor 2 expression. However, we, and others, have demonstrated that approximately 30{\%} of TNBCs express estrogen receptor beta (ERβ), a nuclear hormone receptor and potential drug target. Treatment of ERβ expressing MDA-MB-231 cells with estrogen or the ERβ selective agonist, LY500307, was shown to result in suppression of cell proliferation. This inhibitory effect was due to blockade of cell cycle progression. In vivo, estrogen treatment significantly repressed the growth of ERβ expressing MDA-MB-231 cell line xenografts. Gene expression studies and ingenuity pathway analysis identified a network of ERβ down-regulated genes involved in cell cycle progression including CDK1, cyclin B and cyclin H. siRNA mediated knockdown or drug inhibition of CDK1 and CDK7 in TNBC cells resulted in substantial decreases in proliferation regardless of ERβ expression. These data suggest that the tumor suppressive effects of ERβ in TNBC result from inhibition of cell cycle progression, effects that are in part mediated by suppression of CDK1/7. Furthermore, these data indicate that blockade of CDK1/7 activity in TNBC may be of therapeutic benefit, an area of study that has yet to be explored.",
keywords = "CDK, Cell cycle, ERβ, Estrogen, TNBC",
author = "Reese, {Jordan M.} and Bruinsma, {Elizabeth S.} and Monroe, {David G} and Vivian Negron and Suman, {Vera Jean} and Ingle, {James N.} and Goetz, {Matthew Philip} and Hawse, {John R}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.21787",
language = "English (US)",
volume = "8",
pages = "96506--96521",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "57",

}

TY - JOUR

T1 - ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer

AU - Reese, Jordan M.

AU - Bruinsma, Elizabeth S.

AU - Monroe, David G

AU - Negron, Vivian

AU - Suman, Vera Jean

AU - Ingle, James N.

AU - Goetz, Matthew Philip

AU - Hawse, John R

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Triple negative breast cancer (TNBC), which comprises approximately 15% of all primary breast cancer diagnoses, lacks estrogen receptor alpha, progesterone receptor and human epidermal growth factor receptor 2 expression. However, we, and others, have demonstrated that approximately 30% of TNBCs express estrogen receptor beta (ERβ), a nuclear hormone receptor and potential drug target. Treatment of ERβ expressing MDA-MB-231 cells with estrogen or the ERβ selective agonist, LY500307, was shown to result in suppression of cell proliferation. This inhibitory effect was due to blockade of cell cycle progression. In vivo, estrogen treatment significantly repressed the growth of ERβ expressing MDA-MB-231 cell line xenografts. Gene expression studies and ingenuity pathway analysis identified a network of ERβ down-regulated genes involved in cell cycle progression including CDK1, cyclin B and cyclin H. siRNA mediated knockdown or drug inhibition of CDK1 and CDK7 in TNBC cells resulted in substantial decreases in proliferation regardless of ERβ expression. These data suggest that the tumor suppressive effects of ERβ in TNBC result from inhibition of cell cycle progression, effects that are in part mediated by suppression of CDK1/7. Furthermore, these data indicate that blockade of CDK1/7 activity in TNBC may be of therapeutic benefit, an area of study that has yet to be explored.

AB - Triple negative breast cancer (TNBC), which comprises approximately 15% of all primary breast cancer diagnoses, lacks estrogen receptor alpha, progesterone receptor and human epidermal growth factor receptor 2 expression. However, we, and others, have demonstrated that approximately 30% of TNBCs express estrogen receptor beta (ERβ), a nuclear hormone receptor and potential drug target. Treatment of ERβ expressing MDA-MB-231 cells with estrogen or the ERβ selective agonist, LY500307, was shown to result in suppression of cell proliferation. This inhibitory effect was due to blockade of cell cycle progression. In vivo, estrogen treatment significantly repressed the growth of ERβ expressing MDA-MB-231 cell line xenografts. Gene expression studies and ingenuity pathway analysis identified a network of ERβ down-regulated genes involved in cell cycle progression including CDK1, cyclin B and cyclin H. siRNA mediated knockdown or drug inhibition of CDK1 and CDK7 in TNBC cells resulted in substantial decreases in proliferation regardless of ERβ expression. These data suggest that the tumor suppressive effects of ERβ in TNBC result from inhibition of cell cycle progression, effects that are in part mediated by suppression of CDK1/7. Furthermore, these data indicate that blockade of CDK1/7 activity in TNBC may be of therapeutic benefit, an area of study that has yet to be explored.

KW - CDK

KW - Cell cycle

KW - ERβ

KW - Estrogen

KW - TNBC

UR - http://www.scopus.com/inward/record.url?scp=85033776586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033776586&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21787

DO - 10.18632/oncotarget.21787

M3 - Article

AN - SCOPUS:85033776586

VL - 8

SP - 96506

EP - 96521

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 57

ER -